Trial Profile
Randomized controlled trial of tolvaptan and carperitide to fluid retention in patients with congestive heart failure
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary) ; Carperitide
- Indications Decompensated heart failure
- Focus Therapeutic Use
- Acronyms AVCMA
- 17 Nov 2013 Results of an analysis based on LVEF presented at the 86th Annual Scientific Sessions of the American Heart Association.
- 17 Nov 2013 Status changed from recruiting to completed.
- 04 Sep 2013 Primary endpoint 'Urinary-output' has been met.